Cbmg Holdings News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cbmg holdings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cbmg Holdings Today - Breaking & Trending Today

CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

/PRNewswire/ Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the. ....

United States , Tony Bizuo Liu , Sarah Kelly , Communications Investor Relations , Company Contact , Drug Administration , Prnewswire Cellular Biomedicine Group Inc , Office Of Orphan Products Development , Cellular Biomedicine Group Inc , Biomedicine Group , Regenerative Medicine Advanced Therapy , Fast Track Designation , Ann Arbor , Orphan Products Development , Orphan Drug Designation , Follicular Lymphoma , Multiple Myeloma , Knee Osteoarthritis , Cbmg Holdings ,

CBMG Holdings' Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Patients Following Relapse to an anti-CD19 CAR-T Therapy

Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced early promising safety and efficacy results of C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy. Patients who fail anti-CD19 CAR-T therapy generally have a dismal prognosis and are an important group with high unmet medical needs. This abstract was recently presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, China. ....

United States , Tony Bizuo Liu , Aibin Liang , Sarah Kelly , Communications Investor Relations , American Society Of Clinical Oncology , Institute Of Hematology Blood Diseases Hospital , Company Contact , Professor Of Department Hematology , Tongji University School Of Medicine , Clinical Oncology , Annual Meeting , Principal Investigator , Shanghai Tongji Hospital , Tongji University School , Blood Diseases Hospital , Knee Osteoarthritis , Cbmg Holdings , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries , ஒன்றுபட்டது மாநிலங்களில் , சாரா கெல்லி , தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , நிறுவனம் ஆஃப் ஹீமாட்டாலஜி இரத்தம் நோய்கள் மருத்துவமனை ,

CBMG Holdings' Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Early Promising Clinical Efficacy and Favorable Safety Profile in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This work was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine.
Additionally, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted the Company an orphan drug designation (ODD) to C-CAR039, for the treatment of follicular lymphoma, an indolent form of Non-Hodgkin s Lymphoma. ....

United States , Tony Bizuo Liu , Aibin Liang , Kaplan Meyer , Sarah Kelly , Communications Investor Relations , American Society Of Clinical Oncology , Company Contact , Drug Administration , Tongji University School Of Medicine , Professor Of Department Hematology , Office Of Orphan Products Development , Clinical Oncology , Annual Meeting , Principal Investigator , Shanghai Tongji Hospital , Tongji University School , Orphan Products Development , Ann Arbor Stage , Knee Osteoarthritis , Cbmg Holdings , ஒன்றுபட்டது மாநிலங்களில் , கபிலன் மேயர் , சாரா கெல்லி , தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,

CBMG Holdings Announces Data from Two CAR-T Clinical Studies Selected for Podium Presentations at ASCO Annual Meeting

nd generation novel bi-specific CAR-T therapy targeting both CD19 and CD20 antigens
Indications: Relapsed/refractory B-cell non-Hodgkin s lymphoma (B-NHL)
C-CAR039 has been developed as a novel 2nd generation 4-1BB bi-specific CAR-T targeting both CD19 and CD20 antigens with an optimized bi-specific antigen binding domain. C-CAR039 can eradicate CD19/CD20 single or double positive tumor cells
in vitro and
invivo. The tissue cross reactivity and whole genome membrane proteome array studies further confirmed the specificity of C-CAR039.
C-CAR039 demonstrated a favorable safety profile and promising efficacy in this early clinical trial in patients with r/r B-NHL that might allow it to differentiate from existing therapies. The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies. These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response. ....

United States , Sarah Kelly , Communications Investor Relations , American Society Of Clinical Oncology , Company Contact , Laboratory Of Cell Therapy , Application Center , Cell Therapy Technology Innovation , Ge Healthcare , Clinical Oncology , Annual Meeting , Developmental Therapeutics , Thermo Fisher , Knee Osteoarthritis , Investor Relations , Cbmg Holdings , ஒன்றுபட்டது மாநிலங்களில் , சாரா கெல்லி , தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , நிறுவனம் தொடர்பு , ஆய்வகம் ஆஃப் செல் சிகிச்சை , விண்ணப்பம் மையம் , செல் சிகிச்சை தொழில்நுட்பம் கண்டுபிடிப்பு , கே சுகாதாரம் , மருத்துவ புற்றுநோயியல் ,